MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-05-2024
Catalent Total Shareholders Equity 2011-2026 | CTLT
Annual Total Shareholders Equity Catalent
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.6 B | 4.61 B | 4.78 B | 3.92 B | 2.9 B | 1.68 B | 1.09 B | 724 M | 636 M | 634 M | -371 M | -410 M | -351 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.78 B | -410 M | 1.8 B |
Quarterly Total Shareholders Equity Catalent
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.54 B | 3.6 B | 3.61 B | 3.69 B | 3.84 B | 4.61 B | 4.7 B | 4.91 B | 4.7 B | 4.78 B | 4.63 B | 4.48 B | 4.02 B | 3.92 B | 3.71 B | 3.46 B | 3.07 B | 2.9 B | 2.9 B | 1.72 B | 1.65 B | 1.68 B | 1.68 B | 1.56 B | 1.53 B | 1.09 B | 1.09 B | 1.01 B | 1.04 B | 724 M | 724 M | 588 M | 614 M | 636 M | 636 M | 607 M | 597 M | 634 M | 634 M | 493 M | 504 M | -371 M | -371 M | - | - | -411 M | - | - | - | -351 M | - | - | - | -210 M | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.91 B | -411 M | 2.06 B |
Total Shareholders Equity of other stocks in the Drug manufacturers industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
17 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-808 K | - | 0.86 % | $ 117 M | USA |
 |
China Pharma Holdings
CPHI
|
7.75 M | $ 0.57 | -9.62 % | $ 9.95 M |  China |
 |
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
2.13 B | $ 3.32 | 0.3 % | $ 86.3 M |  Canada |
 |
Athenex
ATNX
|
-6.51 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | - | - | $ 2.06 B |  France |
 |
DURECT Corporation
DRRX
|
14.8 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
649 M | $ 8.01 | -0.5 % | $ 410 M | USA |
 |
Endo International plc
ENDP
|
-6.6 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.01 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
557 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
22.9 M | $ 3.13 | 2.62 % | $ 44 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
265 M | - | - | $ 193 M | Canada |
 |
Bausch Health Companies
BHC
|
-1.02 B | $ 4.99 | -2.25 % | $ 1.82 B | Canada |
 |
Pacira BioSciences
PCRX
|
778 M | $ 23.2 | 2.43 % | $ 1.07 B | USA |
 |
Harrow Health
HROW
|
52.4 M | $ 35.2 | 3.53 % | $ 1.29 B | USA |
 |
PetIQ
PETQ
|
223 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
35.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Perrigo Company plc
PRGO
|
2.94 B | $ 9.64 | 0.73 % | $ 1.34 B | USA |
 |
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | USA |
 |
Evolus
EOLS
|
-23.1 M | $ 4.43 | -5.34 % | $ 286 M | USA |
 |
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | USA |
 |
Sundial Growers
SNDL
|
270 M | $ 1.37 | 0.74 % | $ 3.37 M | Canada |
 |
Rockwell Medical
RMTI
|
21.3 M | $ 1.03 | 0.98 % | $ 24 M | USA |
 |
Relmada Therapeutics
RLMD
|
86.5 M | $ 6.1 | 4.1 % | $ 241 M | USA |
 |
OrganiGram Holdings
OGI
|
300 M | $ 1.34 | -1.47 % | $ 402 M | Canada |
 |
SCYNEXIS
SCYX
|
49.4 M | $ 0.9 | 2.8 % | $ 44.9 M | USA |
 |
Jupiter Wellness
JUPW
|
-2.17 M | - | - | $ 33.6 M | USA |
 |
Solid Biosciences
SLDB
|
180 M | $ 6.68 | -6.44 % | $ 585 M | USA |
 |
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 2.34 | -8.24 % | $ 2.9 M | USA |
 |
Organogenesis Holdings
ORGO
|
263 M | $ 2.41 | -2.43 % | $ 317 M | USA |
 |
Canopy Growth Corporation
CGC
|
487 M | $ 0.96 | -0.87 % | $ 103 M | Canada |
 |
Tilray
TLRY
|
3.32 B | $ 6.66 | 3.26 % | $ 4.12 B | Canada |
 |
Assertio Holdings
ASRT
|
94 M | $ 16.51 | 17.93 % | $ 106 M | USA |
 |
TherapeuticsMD
TXMD
|
29.3 M | $ 2.29 | -0.87 % | $ 23.9 M | USA |
 |
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | USA |
 |
Veru
VERU
|
32.3 M | $ 2.29 | -0.43 % | $ 309 M | USA |
 |
Viatris
VTRS
|
20.5 B | $ 13.36 | 0.53 % | $ 16 B | USA |
 |
cbdMD
YCBD
|
1.96 M | $ 0.77 | 1.06 % | $ 3.32 M | USA |
 |
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
46.2 M | - | - | $ 55.5 M | USA |